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Rare and low frequency genomic variants
impacting neuronal functions modify
the Dup7q11.23 phenotype
Farah Qaiser1,2, Yue Yin2, Carolyn B. Mervis3, Colleen A. Morris4, Bonita P. Klein‑Tasman5, Elaine Tam6,
Lucy R. Osborne1,6 and Ryan K. C. Yuen1,2*

Abstract
Background: 7q11.23 duplication (Dup7) is one of the most frequent recurrent copy number variants (CNVs) in
individuals with autism spectrum disorder (ASD), but based on gold-standard assessments, only 19% of Dup7 carriers
have ASD, suggesting that additional genetic factors are necessary to manifest the ASD phenotype. To assess the con‑
tribution of additional genetic variants to the Dup7 phenotype, we conducted whole-genome sequencing analysis of
20 Dup7 carriers: nine with ASD (Dup7-ASD) and 11 without ASD (Dup7-non-ASD).
Results: We identified three rare variants of potential clinical relevance for ASD: a 1q21.1 microdeletion (Dup7-nonASD) and two deletions which disrupted IMMP2L (one Dup7-ASD, one Dup7-non-ASD). There were no significant dif‑
ferences in gene-set or pathway variant burden between the Dup7-ASD and Dup7-non-ASD groups. However, overall
intellectual ability negatively correlated with the number of rare loss-of-function variants present in nervous system
development and membrane component pathways, and adaptive behaviour standard scores negatively correlated
with the number of low-frequency likely-damaging missense variants found in genes expressed in the prenatal
human brain. ASD severity positively correlated with the number of low frequency loss-of-function variants impacting
genes expressed at low levels in the brain, and genes with a low level of intolerance.
Conclusions: Our study suggests that in the presence of the same pathogenic Dup7 variant, rare and low frequency
genetic variants act additively to contribute to components of the overall Dup7 phenotype.
Keywords: 7q11.23 duplication syndrome, Autism spectrum disorder, Phenotypic variability, Single nucleotide
variant, Copy number variant, Whole genome sequencing
Background
Duplication of the 7q11.23 region (referred to as Dup7)
[1] results in a rare complex neurodevelopmental disorder (MIM 609757) with an estimated prevalence of one in
7500–20,000 individuals [2, 3]. Individuals with a Dup7
copy number variant (CNV) have common Dup7 characteristics including distinctive craniofacial features (i.e.,
*Correspondence: ryan.yuen@sickkids.ca
1
Department of Molecular Genetics, University of Toronto, Toronto, ON,
Canada
Full list of author information is available at the end of the article

macrocephaly, brachycephaly, broad forehead, straight
eyebrows, deep-set eyes, a broad nasal tip with low insertion of the columella, a short philtrum, thin vermillion of
the upper lip, minor ear anomalies and facial asymmetry). Structural brain anomalies include ventriculomegaly, decreased white matter volume, and cerebellar vermis
hypoplasia, while abnormal neurological findings include
hypotonia, abnormalities of gait and station, adventitious
movements, seizure disorder, and developmental coordination disorder [4–6]. In addition, common Dup7 characteristics include aortic dilation, developmental delay,
low-average intellectual ability, speech sound disorder,
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social anxiety disorder, selective mutism, and autism
spectrum disorder (ASD) [4–6].
Over the past decade, studies have pointed to a strong
association between Dup7 and ASD, with Dup7 identified as one of the ten most frequently (0.2%) recurring
CNVs found in children with ASD [2, 7–12]. We previously conducted the first systematic characterization of
ASD symptomatology in a group of 63 children (aged
4–17 years) with Dup7, finding evidence for an elevated
risk of ASD, as 33% of the cohort screened positive for
possible ASD [3]. In our subsequent study of an overlapping sample, 19% of the participants with Dup7 received
a clinical diagnosis of ASD following gold-standard
assessments [4, 5, 9]. Interestingly, in the reciprocal
deletion of the 7q11.23 region, which causes WilliamsBeuren syndrome (WBS, MIM 194050), the prevalence
of ASD symptomatology and diagnosis is also considerably higher than in the general population [13, 14].
Dup7 is a significant ASD risk factor, but despite having
the same shared CNV, most individuals with Dup7 do not
meet the criteria for ASD diagnosis using a gold-standard
diagnostic approach [9]. This phenomenon of incomplete
penetrance and phenotypic variability has been observed
in a number of neuropsychiatric phenotypes, including
those associated with syndromic or multigenic CNVs,
and single genes [15–19]. For example, the 22q11 deletion syndrome (22q11DS) is characterized by significant
differences in the penetrance of congenital heart defects,
schizophrenia and ASD. A recent study found that 20% of
22q11DS carriers with ASD had a second variant within
the mGluR5 network in contrast to only 2% of 22q11DS
carriers who did not have ASD, suggesting that a ‘second
hit’ significantly contributes to ASD risk in 22q11DS [17].
Similarly, Pizzo et al. [16] assessed the contribution of
rare variants in individuals with different primary pathogenic variants, finding that the number of additional hits
correlated with the variability and severity of the overall
clinical phenotype. Such studies add support to the ‘multiple hit’ model, which proposes that syndromic CNVs
exhibit incomplete penetrance and variable expressivity
for ASD and instead require additional genetic factors—
often referred to as ‘second hits’ or modifiers—in order
for individuals to present with ASD [16, 18, 20].
However, there are challenges associated with the
multiple hit model, as not all studies have successfully
identified additional genetic factors to explain phenotypic variability. For example, Masson et al. [21] carried
out whole-exome sequencing (WES) and chromosomal
microarray analysis (CMA) for six individuals with WBSASD but did not identify any secondary variants which
could explain the presence of ASD in these individuals.
Such studies highlight the need to utilize methods that
allow for a thorough examination of the different variants
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present in an individual’s genetic background, which
will allow for a better understanding of incomplete penetrance and phenotypic variability.
In this study, we carry out the first whole-genome
sequencing (WGS) analysis to examine the role of rare
(< 1%) and low-frequency (< 5%) variants in the development of ASD in Dup7 carriers. WGS has the potential to
identify nearly all forms of genetic variation, including
single nucleotide variants (SNVs), indels and CNVs. Previous studies have demonstrated the advantages of WGS
for ASD molecular diagnosis, such as a higher molecular
diagnostic rate and the ability to detect non-coding variants [22–26]. Since prior studies [15–19, 27] have successfully identified rare secondary variants in individuals
with ASD, we carried out rare variant analysis in this
Dup7 cohort to identify potential modifiers. By examining the rare and low frequency damaging variants present
in each Dup7 carrier’s genetic background, we aimed
to better understand how additional variants modulate
neuropsychiatric phenotypes in individuals carrying the
same primary pathogenic variant.

Results
Whole‑genome sequencing (WGS) and chromosomal
microarray analysis (CMA)

Each participant carried a classic Dup7 CNV. For 79.2%
of the participants, we were able to determine if the CNV
was de novo (17 participants; 71%) or inherited (two participants; 4%; one from each group), and the CNV parent-of-origin. The pattern of CNV parent-of-origin was
similar for the two groups: four maternal, five paternal
for Dup7-ASD; six maternal, four paternal for Dup7non-ASD (Fisher exact test, P = 0.656). In terms of clinical characteristics, there were no significant differences
in sex, age at assessment, or General Conceptual Ability (GCA; similar to IQ) standard scores (SS) between
the Dup7-ASD and the Dup7-non-ASD groups (Fig. 1;
Additional file 1: Table S3). However, as expected, the
Dup7-ASD group had a significantly higher ASD symptom calibrated severity score (CSS) than the Dup7-nonASD group (P = 8.43 × 10–7) (Fig. 1; Additional file 1:
Table S3). The Dup7-ASD group also had a significantly
lower Broad Independence standard score (BroadInd SS,
P = 0.010), which is a measure of overall adaptive behavior ability, than the Dup7-non-ASD group (Fig. 1; Additional file 1: Table S3).
We sequenced the genomes from 24 Dup7 carriers, with an average of 43.9 × coverage across all samples (Additional file 1: Table S2). One individual had a
greater than expected number of rare CNVs and was thus
excluded from downstream analyses (Additional file 1:
Figure S1, Table S2). When compared to reference samples from the 1000 Genomes project, ancestry analysis
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Fig. 1 Comparison of demographic and clinical characteristics between the Dup7-ASD and Dup7-non-ASD groups. Boxplots comparing the
following clinical characteristics between the Dup7-ASD and the Dup7-non-ASD groups: a age (P = 0.713); b General Conceptual Ability standard
score (GCA; similar to IQ) from the Differential Ability Scales-II (P = 0.319); c Calibrated severity score from the ADOS-2 (P = 7.40 × 10–7); and d Broad
Independence standard score from the Scales of Independent Behavior-Revised (P = 0.01). Statistically significant differences are marked with an
asterisk, where P values less than 0.05 are marked with a single asterisk, P values less than 0.01 are marked with two asterisks, and P values less than
0.001 are marked with three asterisks

found that most of the Dup7 carriers were either European (n = 18, 75%) or American (n = 3, 12.5%) (Additional file 1: Figure S2, Methods). Of the remaining three
Dup7 carriers, one clustered with the South Asian ancestry group, while the other two did not cluster with any
group. These three individuals were excluded for potential confounding effects in downstream analyses. Lastly,
kinship analysis confirmed that the participants within
the cohort were unrelated (Additional file 1: Figure S3).
Overall, a total of nine participants with Dup7-ASD
and 11 with Dup7-non-ASD were used in downstream
analyses, where we detected an average of 4,685,522
indels and SNVs, and 661 CNVs per genome (Additional file 1: Table S2). Examining rare variants only, we
detected an average of 185 indels and SNVs, and 35.4
CNVs impacting coding regions per genome (Additional
file 1: Figure S1; Table S3). For the 20 participants used

in downstream analyses, there were no significant differences in the distributions of Dup7 CNV size between
the Dup7-ASD (Mean: 1,658,333 bp, SD: 175,468 bp) and
Dup7-non-ASD (1,564,455 bp, SD: 33,721 bp) groups
(Mann–Whitney U test, z = 0.80, P = 0.424) (Additional
file 1: Table S4).
Clinically relevant rare variant analysis

We identified three rare variants of potential clinical
relevance to ASD: a pathogenic 1q21.1 microdeletion
in an individual with Dup7-non-ASD and two different rare deletions which disrupt IMMP2L at the 7q31.1
locus (one Dup7-ASD, one Dup7-non-ASD) (Table 1).
These three rare CNVs impact both the coding and noncoding regions of the genome. The latter two CNVs were
of different sizes, and both were classified as VUS. We
did not identify any SNVs or indels which met clinical
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Table 1 Rare clinically relevant variants identified in the Dup7 cohort
Group*

Gene(s)

Variant type Variant Chromosome coordinates
(GRCh37/hg19)

Variant category

Dup7-non-ASD ACP6, BCL9, CHD1L, FMO5, GJA5, GJA8,
GPR89B, NBPF10, NBPF11, NBPF12,
NBPF20, NBPF8, PRKAB2

CNV

DEL

Chr1:146,303,401- 147,891,400
Size: 1,588,000 bp

Pathogenic

Dup7-non-ASD IMMP2L, LRRN3

CNV

DEL

Chr7:110,347,001- 110,883,800
Size: 536,800 bp

Variant of uncertain significance

Dup7-ASD

CNV

DEL

Chr7:111,120,394–111,351,748
Size: 231,355 bp

Variant of uncertain significance

IMMP2L

CNV copy number variant, DEL deletion
*

Each CNV listed here is found in a different participant

significance per American College of Medical Genetics
and Genomics (ACMG) guidelines. Overall, there was no
significant difference in rare variant findings between the
Dup7-ASD group and the Dup7-non-ASD group.
Burden analysis of genomic variants

To assess the correlation between phenotypic measures
and the burden of variants (either rare or low frequency)
in participants with Dup7, we performed regression
analysis and found that GCA SSs were negatively correlated with the burden of (1) low frequency LoF variants
(P = 0.012), (2) a combination of low frequency LoF and
missense variants (P = 0.022), and (3) rare non-Dup7
CNVs (P = 0.016) (Additional file 1: Table S5). There was
no significant correlation between the burden of genomic
variants and the remaining phenotypic measures (i.e.

Dup7-ASD vs. Dup7-non-ASD, BroadInd SS, CSS)
(Additional file 1: Table S5).
Correlation of function and pathway with phenotypic
outcomes

To assess the contribution of likely damaging rare and
low frequency variants to the overall Dup7 neuropsychiatric phenotype, we conducted regression modelling
to identify correlations between phenotypic outcomes
and different burden variables in gene-sets (ASD-risk,
Neuroset) or pathways (GO, KEGG) (Table 2). Upon
examining individual variant types, we found that
BroadInd SSs (where higher scores indicate better
adaptive behaviour skills) were negatively correlated
with likely damaging low frequency missense variants
enriched in genes expressed in the prenatal human
brain (P = 0.003; FDR = 0.078, Fig. 2a). We observed

Table 2 Biological processes significantly enriched among genes carrying a higher number of rare or low frequency
variants in Dup7 carriers
Outcome
phenotype

Variable

Pathway
category

Pathway/
function

Number
of genes
in pathway

Number
of observed
variants

BroadInd SS

Likely damaging
missense vari‑
ants (5%)

Neuroset

Brain
Pre-natal (PC1
bottom 33%)

3038

451

CSS

LoF variants (5%)

Neuroset

Brain low/absent
expression

4601

145

0.574

3.19 × 10–3 0.078

LoF variants (5%)

Neuroset

Genic intolerance, 4153
very low (Q1)

164

0.662

5.87 × 10–3 0.078

LoF variants (1%)

Neuroset

Nervous System
Development

1874

8

− 25.2

2.28 × 10–3 0.074

LoF variants (1%)

GO

Side of mem‑
brane
[GO:0098552]

426

3

− 43.0

3.61 × 10–4 0.148

LoF variants (1%)

GO

External Side
of Plasma
Membrane
[GO:0009897]

232

3

− 43.0

3.61 × 10–4 0.148

GCA

B (coefficient) P value

− 2.75

FDR

3.10 × 10–3 0.078

CSS calibrated severity score (from ADOS-2), GCA General Conceptual Ability standard score (from DAS-II), GO gene ontology, LoF loss of function, PC1 principal
component 1, BroadInd SS SIB-R Broad Independence standard score. Percentages in parentheses refer to variant frequency
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Fig. 2 Volcano plot of relationship between BroadInd SS and likely damaging variants present in neuroset pathways. Volcano plot of likely
damaging missense variants (5% frequency level) expressed in neuroset pathways for the BroadInd SS outcome variable. Labelled functions met a P
value cut-off of at most 0.05 and have a false discovery rate (FDR) of ≤ 0.15

a negative correlation between GCAs (where higher
scores indicate higher intellectual ability) and rare likely
damaging LoF variants enriched in nervous system
development (P = 0.002; FDR = 0.074, Fig. 3a), and two
membrane component GO pathways (P = 3.61 × 10–4;
FDR = 0.148, Fig. 3B). Lastly, CSSs (where higher scores
are associated with higher levels of ASD symptoms)
were positively correlated with low frequency LoF variants enriched in genes expressed in low levels in the
brain (P = 0.003; FDR = 0.078, Fig. 4) and in genes with

a very low level of intolerance (P = 0.006; FDR = 0.078,
Fig. 4).
Similarly, to assess the contribution of non-coding
variants which cause cryptic splicing to the overall Dup7
neuropsychiatric phenotype, we repeated the above
regression modelling analyses, with the inclusion of variants with a high likelihood of disrupting splicing in the
LoF SNV burden variable (1%, 5%) (Additional file 1:
Table S6). We detected a total of 29 rare and 46 low frequency variants with a high likelihood of disrupting

Fig. 3 Volcano plot of relationship between GCA and likely damaging variants in GO and neuroset pathways. Volcano plot of rare LoF variants (1%
frequency level) expression in neuroset (a) and GO (b) pathways for the GCA outcome variable. Labelled functions met a P value cut-off of at most
0.05 and have a false discovery rate (FDR) of ≤ 0.15. GCA DAS-II General Conceptual Ability standard score, GO gene ontology, LoF loss of function
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Fig. 4 Volcano plot of relationship between CSS and likely damaging variants in GO and neuroset pathways. Volcano plot of low frequency likely
damaging LoF (5%) in neuroset pathways for the CSS outcome variable. Labelled functions met a P value cut-off of at most 0.05 and have a false
discovery rate (FDR) of ≤ 0.15. CSS ADOS-2 calibrated severity score, GO gene ontology, LoF loss of function

splicing, as predicted by SpliceAI [28]. We found a significant correlation in two of the aforementioned pathways.
Specifically, there were significant positive correlations
between CSSs and (i) both rare (P = 0.004; FDR = 0.091)
and low frequency (P = 0.002; FDR = 0.036) LoF variants
enriched in genes expressed in low levels in the brain,
and (ii) low frequency LoF variants impacting genes with
a very low level of intolerance (P = 0.011; FDR = 0.105).

Discussion
In this study, we present the first systematic WGS analysis of participants with Dup7, with and without ASD,
to explore the role of additional genetic variants in the
development of ASD in 7q11.23 duplication syndrome.
A comparison of the genetic background between the
individuals with Dup7-ASD (n = 9) and the individuals
with Dup7-non-ASD (n = 11) found no significant differences in variant findings between the two groups, but
instead showed that in the presence of the same primary
pathogenic Dup7 variant, there are additional variants
involved, which likely act additively to contribute to the
overall intellectual ability and adaptive behavior components of the Dup7 phenotype. These results suggest that
in addition to the primary pathogenic variants, rare and
low frequency variants present in the genetic background
modulate the clinical variability seen in neurodevelopmental disorders (NDDs) such as Dup7.
We identified one pathogenic 1q21.1 deletion and
two VUS CNVs of interest impacting IMMP2L in this
Dup7 cohort, representing 15% of the samples investigated. Haploinsufficiency at the 1q21.1 locus is associated with various phenotypes, and past studies point to
1q21.1 duplications being more strongly associated with

ASD or ASD-like features than deletions [29, 30]. This
is consistent with the finding of a 1q21.1 deletion in an
individual with Dup7-non-ASD in our cohort. We also
identified two deletions which disrupted IMMP2L and
were found in both Dup7-ASD and Dup7-non-ASD participants. Of note, IMMP2L encodes the second subunit
of the inner mitochondrial membrane peptidase complex
and has previously been reported as a potential candidate gene associated with ASD, Tourette syndrome and
other NDDs [31–33]. These CNV findings add to the
available evidence regarding IMMP2L’s potential role in
neurodevelopment, but its contribution to ASD remains
uncertain given that a CNV disrupting solely IMMP2L
was identified in a Dup7-non-ASD individual who had an
ADOS-2 CSS of 1 (the lowest possible score).
There were no significant differences in Dup7 size,
gene-set or pathway variant burden between the Dup7ASD and Dup7-non-ASD groups. We did identify statistically significant correlations between continuous
phenotypic measures (CSS, GCA and BroadInd SS) and
rare or low frequency variants in pathways impacting
neuronal functions. The implicated pathways include
genes found in the Dup7 region, such as GTF2I, ELN
(the structural protein elastin) and CLIP2 (a cytoplasmic linker protein), although no likely damaging variants were identified in any of the genes within the Dup7
region, with the exception of CLIP2. Of particular interest
is the finding that the adaptive behaviour SSs of individuals with Dup7 were negatively correlated with a higher
burden of rare likely damaging missense variants in genes
expressed in the prenatal human brain. Here, implicated
variants included a missense variant in CLIP2, and variants in known ASD-risk genes and/or neuropsychiatric
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phenotypes, such as SETD5 (a methyltransferase) and
CHD2 (a chromodomain helicase DNA-binding protein).
Similarly, we found that overall intellectual ability SSs
were negatively correlated with rare likely damaging LoF
variants in nervous system development and two membrane GO component pathways, where enriched variants
were present in genes encoding receptors (e.g. CHRNA3,
AGER) and cell adhesion molecules (e.g. PCDHB9,
PCDHA8). While some of these enriched variants merit
further investigation as they are either present in the
Dup7 region or in genes associated with known disorders, it is important to note that none of these variants
meet pathogenicity criteria as per ACMG guidelines.
Functional characterization of these implicated variants
is necessary to understand how they interact with the
primary variant (Dup7), other rare and low frequency
variants in the genetic background, and how they ultimately modulate the Dup7-associated phenotype.
Taken together, our findings point to a model where
rather than discrete second hits, the complexity of clinical characteristics in Dup7-associated neuropsychiatric phenotypes is modulated by rare and low frequency
variants, which are present in the genetic background in
addition to the primary pathogenic Dup7 variant. This
study highlights the power of pathway analyses and the
correlation of quantitative traits toward understanding
how additional rare variants in the genetic background
modulate neurodevelopmental disorders.
Our results should be interpreted in the context of the
following limitations. Firstly, we only carried out WGS
analysis for the Dup7 carriers in this study, and not
parents, thus the inheritance of the identified variants
remains unknown. We only examined SNVs and CNVs
in the Dup7 cohort, and thus cannot rule out that differences or a burden of other variant types (such as structural variants) may be able to differentiate between the
Dup7-ASD and Dup7-non-ASD groups. Finally, it should
be noted that because this is a small cohort (n = 20), we
could not evaluate variants with smaller effect sizes, such
as common variants (i.e. ≥ 5% frequency) and non-coding
variants, other than those which disrupt splicing. Instead,
this study can serve as a baseline when evaluating phenotypic variability in larger Dup7 cohorts.
To date, there has been no analysis of exome or genome
data to investigate possible genetic factors in individuals
with both Dup7 and ASD, making our study the first to
systematically examine the role of rare and low frequency
variants in Dup7-ASD. However, exome data have been
analyzed for individuals with both ASD and WBS [21,
34]. Codina-Sola et al. (2019) conducted WES in eight
individuals with WBS-ASD, where seven (87.5%) of the
7q11.23 deletions were paternal in origin, and a total of
five inherited rare variants were identified in ASD-related
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or loss-of-function intolerant genes, as well as one de
novo LoF variant. In contrast, Masson et al. (2019) identified no clinically relevant secondary hits in their WBSASD cohort (n = 6), and reported 7q11.23 deletions of
maternal (n = 4) and paternal (n = 1) origin in individuals with WBS-ASD. Across the two studies, there is no
evidence of an imprinting effect in the WBS-ASD phenotype. Similarly, in our cohort, the pattern of CNV
parent-of-origin was similar for both the Dup7-ASD and
Dup7-non-ASD groups, providing no evidence of an
imprinting effect in the Dup7-ASD phenotype.
As mentioned earlier, the phenomenon of incomplete
penetrance and phenotypic variability has been reported
in multiple neuropsychiatric phenotypes, suggesting that
secondary variants may be necessary for ASD manifestation [15–19, 27]. In our study, we did not identify discrete
second hits which could explain the development of ASD
in individuals with Dup7, but instead, similar to Pizzo
et al. (2018), we identified correlations between different phenotypic measures (such as ASD symptom severity and intellectual ability) and genetic variants enriched
in related molecular pathways, suggesting that variants
present in the genetic background play a critical role in
phenotypic variability.

Conclusions
Overall, in this study, WGS characterization found that
in the presence of the same pathogenic Dup7 variant,
additional genetic variants also have an impact on the
phenotype. Our findings suggest that neuropsychiatric
phenotypes associated with particular syndromes are
subject to modulation by additional genetic variants.
Thus, assessing the role of rare and low frequency variants present in the genetic background should improve
the phenotypic correlation in CNV-associated or monogenic disorders.
Methods
Participant cohort

We recruited 24 children with Dup7: 12 individuals with
Dup7-ASD (case) and 12 individuals with Dup7-nonASD (control) who were pairwise matched as closely
as possible on sex, age and ethnicity (Additional file 1:
Table S1). The presence of classic Dup7 was confirmed in
each participant through chromosomal microarray analysis (CMA) using various commercially available platforms and/or quantitative PCR (qPCR). When possible,
parents were tested for Dup7, and the parent-of-origin of
de novo CNVs was determined by the analysis of singlecopy microsatellite markers within the Dup7 region [1].
ASD diagnosis was determined using the gold-standard
diagnostic approach [9]. Each participant with Dup7 was
clinically evaluated using three standardized measures:
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the Autism Diagnostic Observation Schedule-2 (ADOS2) [35], the Differential Ability Scales-II (DAS-II) [36],
and the Scales of Independent Behavior-Revised (SIB-R)
[37] (see Additional file 1: Methods). Additional file 1:
Table S1 reports characteristics for each participant,
including sex, ADOS-2 calibrated severity score (CSS, a
measure of severity of autism-related symptoms), SIB-R
Broad Independence standard score (BroadInd SS, a
measure of adaptive behaviour), and DAS-II General
Conceptual Ability standard score (GCA, a measure of
overall intellectual ability similar to IQ) [38]. Individual
ethnicities, Dup7 CNV origins, age at assessment, and
the ADOS-2 module administered are not included in
order to preserve participants’ privacy. Two-sided nonparametric Mann–Whitney U tests were carried out
to compare clinical characteristics between the Dup7ASD and Dup7-non-ASD groups. All procedures were
approved by the Research Ethics Boards of the University
of Toronto and/or the University of Louisville, and written informed consent was obtained from the parents or
legal guardians of all participants.
Whole genome sequencing (WGS)

Genomic DNA was extracted from blood using the
QIAamp DNA Blood Mini Kit (QIAGEN) and then
sequenced using the Illumina HiSeq X platform at The
Centre for Applied Genomics. Reads were aligned to
the reference genome (build GRCh37/hg19) using the
Burrows-Wheeler Aligner (v.0.7.12) as a sorted binary
alignment map (BAM) format [39]. Duplicate reads were
removed by MarkDuplicates from Picard (v.1.133). Local
realignment, quality recalibration and removal of duplicate reads were carried out using the Broad Institute’s
Genome Analysis Toolkit (GATK) (v.3.4-46) for each
genome. Each variant call format (VCF) file was annotated using a custom pipeline based on ANNOVAR,
which included annotating effects (such as non-synonymous, nonsense or frameshift variants) and various
features (e.g. whether the variant occurs in an exonic,
intronic or intergenic region) [40].
To filter for only high-quality variants, the following parameters were applied: (1) autosomal heterozygous variants have a genotype quality (GQ) of ≥ 99, and
an alternative allele fraction (AAF) ≥ 0.3 and ≤ 0.7; (2)
homozygous variants and those on chromosome X have
a GQ ≥ 25 and an AAF > 0.7; and (3) all variants passed
GATK pipeline filters. CNVs were detected using a combination of the ERDS and CNVnator read depth based
algorithms as previously described [41]. In addition, the
SpliceAI tool was used to detect non-coding genetic variants which cause cryptic splicing [28]. To filter for only
high-quality variants, the following parameters were
applied: (1) at least one of the SpliceAI delta scores (i.e.
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acceptor or donor gain/loss) ≥ 0.8; and (2) variants which
impacted inter-genic regions were excluded.
Ancestry and Kinship analyses

Ancestry analyses were conducted using the ancestry
estimating program ADMIXTURE (v.1.3) and PLINK
(v.1.9), where samples from the 1000 Genome Project
were used as reference population groups to generate estimated ancestry fractions for each Dup7 carrier
(see Additional file 1: Methods) [42]. Through principal
component analysis, scatterplots with the top principal components were generated to observe the ancestry
clustering pattern of Dup7 carriers. In addition, using
PLINK-genome, kinship analysis was carried out to generate estimated identity-by-descent (IBD) proportions
to determine the degree of relatedness among the Dup7
carriers.
Rare variant analysis

A rare variant was defined as one which is present in ≤ 1%
of the population in the following databases: the 1000
Genomes project, the Exome Aggregation Consortium,
and the Genome Aggregation Database. This includes
both missense (non-synonymous) and loss-of-function
(LoF) variants, where the latter include frameshift insertions or deletions (indels), nonsense and core splice-site
variants. Rare variants in both the coding and non-coding region were prioritized using annotation features
such as sequence conservation, biological relevance,
probability of LoF intolerance (pLI) scores, genetic mode
of inheritance, and their predicted impact on coding and
non-coding sequence using in silico algorithms, specifically CADD, SIFT, PolyPhen, Provean, MutationAssessor,
MutationTaster, PhyloPMam, and PhyloPVert. Missense
variants with high predicted scores in at least four out of
eight in silico algorithms were considered likely damaging [24, 26].
As per the ACMG interpretation guidelines, rare CNVs
(as called by ERDS and CNVnator from WGS output)
were filtered based on their genomic content, and overlap with CNVs reported in databases such as DECIPHER
and the Database of Genomic Variants [43, 44]. Rare
CNVs were prioritized using various annotation features,
including whether the CNV (i) impacted protein coding
regions or functionally important elements, (ii) if there
was a complete or partial overlap of an established haploinsufficiency genomic region, or (iii) if the reported
phenotype was highly specific or consistent with the
impacted region, when compared to the literature and/or
public databases.
Prioritized rare variants were then classified, as per
ACMG guidelines, into the following categories: pathogenic, likely pathogenic, variant of unknown significance
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(VUS), benign and likely benign [43, 45–47]. Read alignments for variants of interest were manually inspected
using Integrative Genomics Viewer. Variants with a
high likelihood of disrupting splicing, as predicted by
SpliceAI, were not included in this rare variant analysis,
as the interpretation guidelines established by the American College of Medical Genetics and Genomics (ACMG)
are restricted to the evaluation of genetic variants in
canonical ± 1 or 2 splice sites.
Genomic variant burden analysis

The burden of genomic variants was analyzed using the
following regression models in R:
logit(binary outcome variable) = sex + age + burden
variable.
continuous outcome variable = sex + age + burden
variable.
In each model, the number of qualifying variants per
sample at varying frequency levels (either rare [≤ 1%] or
low frequency [< 5%]) were defined as the burden variable to test—which included testing (1) LoF SNVs; (2)
missense SNVs; and (3) non-Dup7 CNVs impacting
both the coding and non-coding regions of the genome.
In the case of missense SNVs, all eight prediction algorithms were tested sequentially i.e. mis_1 refers to one of
the eight algorithms supporting that a missense variant
was likely damaging, mis_2 refers to two supporting algorithms, etc.
Both binary (i.e. Dup7-ASD or Dup7-non-ASD) and
continuous (SIB-R and DAS-II SSs) phenotypic measures were used as outcome variables to construct models for correlation studies. Each model also included the
participant’s sex and age as covariates for potential confounding effects. Control models were constructed using
synonymous variants and non-frameshift indels to see
the potential effect of other confounders. The false discovery rate (FDR) was calculated to account for multiple
comparisons.
For each burden analysis, the target variable had to
meet the following thresholds to reach significance: (1)
the B (raw coefficient) was positive for models using
Dup7-ASD/Dup7-non-ASD or CSS as an outcome variable and negative for models using GCA and BroadInd
SS as an outcome variable; (2) met a P value cut-off of at
most 0.05; and (3) had an FDR value ≤ 0.15. One-tailed
statistics are reported, and corresponding volcano plots
were generated for each model where the target variable
met significance.
Function and pathway enrichment analyses

Similar to the above burden analyses, function and
pathway enrichment analyses on gene-sets with rare
and low frequency variants were carried out on the
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Dup7 cohort using regression models in R. Here, we
correlated the results with categorical and quantitative
phenotypic measures (i.e. Dup7-ASD or Dup7-nonASD, or SIB-R and DAS-II SSs). We tested the following burden variables: (1) LoF SNVs; (2) likely damaging
missense SNVs (as defined above i.e. at least four out of
eight in silico algorithms supported the variant’s likely
damaging effect); and (3) non-Dup7 CNVs. Two different gene-sets were used: (1) a combination of an ASDrelated gene list (consisting of 1132 genes that have
been reported to have an association with ASD) and 51
neuro-related gene-sets i.e., Neuroset (which were collected based on their neural function, brain expression
or neural disease phenotypes); and (2) two commonly
used gene pathway systems: Geno Ontology (GO)
and the Kyoto Encyclopedia of Genes and Genomes
(KEGG), where the gene-set size was limited to 100–
1000 genes [24, 26, 48].
The function and pathway analyses were also repeated
to include non-coding genetic variants with a high likelihood of disrupting splicing, as predicted by SpliceAI,
in the LoF SNV burden variable (1%, 5%).
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